Lopinavir-Ritonavir Treatment for COVID-19 Infection in Intensive Care Unit

Beyls, Christophe; Martin, N.; Hermida, Alexis; Abou-Arab, Osama; Mahjoub, Yazine

doi:10.1161/circep.120.008798

Cited by 31 publications

(27 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Albeit some contradictory studies showed no statistically significant effect on reducing the death rate ( Karolyi et al, 2020 ; Horby et al, 2020 ). A report stated the risk of bradycardia in elderly critically ill COVID-19 patients with RTV plasma overdose ( Beyls et al, 2020 ). Adverse gastrointestinal effects such as diarrhea, nausea and vomiting have been observed in patients treated with LPV/RTV ( Huang Y.-Q.…”

Section: Selected Antivirals Repurposing In Covid-19 Treatmentsmentioning

confidence: 99%

An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?

et al. 2021

View full text Add to dashboard Cite

COVID-19 pandemic has spread worldwide at an exponential rate affecting millions of people instantaneously. Currently, various drugs are under investigation to treat an enormously increasing number of COVID-19 patients. This dreadful situation clearly demands an efficient strategy to quickly identify drugs for the successful treatment of COVID-19. Hence, drug repurposing is an effective approach for the rapid discovery of frontline arsenals to fight against COVID-19. Successful application of this approach has resulted in the repurposing of some clinically approved drugs as potential anti-SARS-CoV-2 candidates. Several of these drugs are either antimalarials, antivirals, antibiotics or corticosteroids and they have been repurposed based on their potential to negate virus or reduce lung inflammation. Large numbers of clinical trials have been registered to evaluate the effectiveness and clinical safety of these drugs. Till date, a few clinical studies are complete and the results are primary. WHO also conducted an international, multi-country, open-label, randomized trials-a solidarity trial for four antiviral drugs. However, solidarity trials have few limitations like no placebos were used, additionally any drug may show effectiveness for a particular population in a region which may get neglected in solidarity trial analysis. The ongoing randomized clinical trials can provide reliable long-term follow-up results that will establish both clinical safety and clinical efficacy of these drugs with respect to different regions, populations and may aid up to worldwide COVID-19 treatment research. This review presents a comprehensive update on majorly repurposed drugs namely chloroquine, hydroxychloroquine, remdesivir, lopinavir-ritonavir, favipiravir, ribavirin, azithromycin, umifenovir, oseltamivir as well as convalescent plasma therapy used against SARS-CoV-2. The review also summarizes the data recorded on the mechanism of anti-SARS-CoV-2 activity of these repurposed drugs along with the preclinical and clinical findings, therapeutic regimens, pharmacokinetics, and drug-drug interactions.

show abstract

Section: Selected Antivirals Repurposing In Covid-19 Treatmentsmentioning

confidence: 99%

An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Authors considered causality as bradycardia occurred at least 48 h after LPV/r initiation, bradycardia resolved after discontinuation or dose reduction of LPV/r, and no alternative cause was found. No correlation was found between LPV/r plasma concentrations and mean heart rate [ 78 ]. Cao et al.…”

Section: Clinical Studiesmentioning

confidence: 99%

Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment

et al. 2021

View full text Add to dashboard Cite

“…According to this result, it was reported that RTV-LPV could increase the risk of bradycardia when used in inflammatory injury conditions and during critical stages of the disease. 18…”

Section: Main Drugs and Therapeutic Compounds In Sars-cov-2 Infectionmentioning

confidence: 99%

“…However, it is recommended to use this drug in patients with respiratory and immunological problems, only in combination with drugs that have proven effectiveness. 29 Reducing the disease symptoms in the early stage, [12][13][14] not accelerating the disease treatment, 16 increasing the risk of bradycardia 18 Remdesivir (RDV) Ebola 19 Accelerating the patient's recovery, having no specific side effects [22][23][24] Favipiravir (FPV) Influenza 26,27 Accelerating the patient's recovery, having few side effects 28,29 Arbidol (ARB) Influenza 30 Having proper performance, [34][35][36][37] having no specific side effects 34 Having good performance in combination with HCQ, reducing mortality, having no special side effects [63][64][65][66][67]69 Teicoplanin Ebola 70,71 Having inhibitory effects on viral infection 70-72…”

Section: Favipiravir (Fpv)mentioning

confidence: 99%

<p>Current Options in the Treatment of COVID-19: A Review</p>

Teimury¹,

Khaledi²

2020

RMHP

View full text Add to dashboard Cite

Novel Coronavirus, also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in December 2019 in China and spread rapidly all around the world infecting many people. To date, no specific vaccines and drugs have been developed for this disease. Also, due to the COVID-19 pandemic and high prevalence of the infected patients, the drugs and the therapies of other past viral epidemics have been used for this disease. Many studies have been performed on the specific treatments to find whether or not they are effective on COVID-19 patients. In this review, we collected information about the most widely used drugs to treat COVID-19 (coronavirus disease 2019) belonging to groups of antivirals, antibiotics, immune modulators, and anticoagulants. Some of these compounds and drugs were used directly by inpatients, so researchers have examined others in laboratory conditions. This study considered the pros and cons of using these treatments separately and together and compared their results. By studying this review, we hope to provide useful information for researchers.

show abstract

Lopinavir-Ritonavir Treatment for COVID-19 Infection in Intensive Care Unit

Cited by 31 publications

References 5 publications

An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?

An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?

Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment

<p>Current Options in the Treatment of COVID-19: A Review</p>

Contact Info

Product

Resources

About